Long‐term survival in thymic epithelial tumors: A single‐center experience from China

Shen, Shengping; Ai, Xinghao; Lu, Shun

doi:10.1002/jso.23256

Cited by 16 publications

(24 citation statements)

References 31 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 5-year survival rate was around 50% for type B3 thymoma, while it was 90% for types B1, AB and A. The 5-year survival rate for type B2 thymoma was about 60% to 70% in previous reports [ 4 , 5 ]. The 5-year survival rate was 62.8% in our study, which is similar to previous reports.…”

Section: Discussionmentioning

confidence: 85%

“…It is generally accepted that surgery is the mainstay treatment, and R0 resection is one of the most independent prognostic factors for thymoma. However, some reports have shown that there was no survival difference for patients who undergo complete resection compared with patient undergoing incomplete resection [ 4 , 11 ]. In the current study, there were DFS and OS differences between complete and incomplete resection patients.…”

Section: Discussionmentioning

confidence: 99%

“…The proportion of B2 types reported is about 20% for all thymomas [ 3 , 4 ]. The B2 type of thymoma has been shown to have a better prognosis than thymic carcinoma and worse than types A, AB and B1 [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment and prognosis of type B2 thymoma

2014

View full text Add to dashboard Cite

BackgroundBecause of the rarity of thymoma, no randomized trials have prospectively detected the prognosis and optimal treatment for type B2 thymoma. The aim of this study is to investigate the treatment and prognosis for patients with type B2 thymoma.MethodsWe retrospectively evaluated the outcome of 42 patients with type B2 thymoma who were treated between 1995 and 2010 in Zhejiang Cancer Hospital. Survival curves were plotted using the Kaplan–Meier method. The Cox proportional hazard model was used for multivariate analysis.ResultsThe current study included 42 patients. The 5-year disease-free survival and overall survival rates were 62.8% and 84.9%, respectively. There were significant differences in disease-free survival and overall survival among different Masaoka stages (both P < 0.001). Univariate and multivariate analysis revealed that Masaoka stage was associated with disease-free survival and overall survival (P = 0.00 and 0.001, respectively).ConclusionsOur results indicate that Masaoka stage affects disease-free survival and overall survival of patients with type B2 thymoma.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment and prognosis of type B2 thymoma

2014

View full text Add to dashboard Cite

show abstract

“… 12 However, some reports have showed that there was no survival difference for patients who underwent complete resection compared with incomplete resection. 9 , 13 In the current study, there was DFS and OS differences between complete and incomplete resection patients with univariate analyses. However, the difference of OS was not significant by multivariate analysis, the reason may be due to the small number of patients in our study.…”

Section: Discussionmentioning

confidence: 50%

“… 3 – 6 The value of resection, radiotherapy, and chemotherapy has remained uncertain for the Masaoka stage 3 thymic carcinoma until now. 7 – 9 The optimal treatment for Masaoka stage 3 thymic carcinoma needs to be defined.…”

Section: Introductionmentioning

confidence: 99%

Treatment and prognosis of Masaoka stage 3 thymic carcinoma: a retrospective study of 32 cases

Sun¹,

Liu²,

Yu³

2015

OTT

View full text Add to dashboard Cite

PurposeThe aim of this study was to investigate the treatment and prognostic factors in patients with Masaoka stage 3 thymic carcinoma.MethodsA retrospective review was conducted of the medical records of patients with Masaoka stage 3 thymic carcinoma between 2000 and 2012 in our institution. Clinical characteristics and prognostic factors were analyzed. Survival curves were plotted using the Kaplan–Meier method. The Cox proportional hazard model was used for multivariate analysis.ResultsThirty-two patients with Masaoka stage 3 thymic carcinoma, operated on in Zhejiang Cancer Hospital, were identified between 2000 and 2012. Among 32 patients, 24 achieved R0 resection. The most common histological subtypes were squamous cell carcinoma (n=15, 46.8%), followed by undifferentiated carcinoma (n=12, 37.5%), and other tumors (n=5, 15.7%). The 5-year disease-free survival and overall survival rates were 56.8% and 61.5%, respectively. Patients with incomplete resection had a significantly worse disease-free survival and overall survival as compared to complete resection with univariate analyses (P-value 0.006 and 0.034, respectively). Multivariate analysis revealed that complete resection was statistically associated with disease-free survival but not overall survival (P-value 0.025 and 0.076, respectively).ConclusionOur results indicated that complete resection could impact the disease-free survival of patients with stage 3 thymic carcinoma.

show abstract

American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma

et al. 2023

View full text Add to dashboard Cite

ImportanceThymic carcinoma is rare, and its oncologic management is controversial due to a paucity of prospective data. For this reason, multidisciplinary consensus guidelines are crucial to guide oncologic management.ObjectiveTo develop expert multidisciplinary consensus guidelines on the management of common presentations of thymic carcinoma.Evidence ReviewCase variants spanning the spectrum of stage I to IV thymic carcinoma were developed by the 15-member multidisciplinary American Radium Society (ARS) Thoracic Appropriate Use Criteria (AUC) expert panel to address management controversies. A comprehensive review of the English-language medical literature from 1980 to 2021 was performed to inform consensus guidelines. Variants and procedures were evaluated by the panel using modified Delphi methodology. Agreement/consensus was defined as less than or equal to 3 rating points from median. Consensus recommendations were then approved by the ARS Executive Committee and subject to public comment per established ARS procedures.FindingsThe ARS Thoracic AUC panel identified 89 relevant references and obtained consensus for all procedures evaluated for thymic carcinoma. Minimally invasive thymectomy was rated as usually inappropriate (regardless of stage) due to the infiltrative nature of thymic carcinomas. There was consensus that conventionally fractionated radiation (1.8-2 Gy daily) to a dose of 45 to 60 Gy adjuvantly and 60 to 66 Gy in the definitive setting is appropriate and that elective nodal irradiation is inappropriate. For radiation technique, the panel recommended use of intensity-modulated radiation therapy or proton therapy (rather than 3-dimensional conformal radiotherapy) to reduce radiation exposure to the heart and lungs.Conclusions and RelevanceThe ARS Thoracic AUC panel has developed multidisciplinary consensus guidelines for various presentations of thymic carcinoma, perhaps the most well referenced on the topic.

show abstract

Long‐term survival in thymic epithelial tumors: A single‐center experience from China

Cited by 16 publications

References 31 publications

Treatment and prognosis of type B2 thymoma

Treatment and prognosis of type B2 thymoma

Treatment and prognosis of Masaoka stage 3 thymic carcinoma: a retrospective study of 32 cases

American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma

Contact Info

Product

Resources

About